Atlas Trials

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Clinical trial NCT02153905 · TERMINATED

Trial details

NCT number
NCT02153905
Sponsor
National Cancer Institute (NCI)
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Breast CancerCervical CancerRenal CancerMelanomaBladder Cancer
Start date
2014-07-03
Primary completion
2018-09-10
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.